Status:
COMPLETED
The Effects of Efalex Active 50+ on Cognitive Performance, Well-being and Cerebral Hemodynamics in Healthy Older Adults
Lead Sponsor:
Northumbria University
Collaborating Sponsors:
Efamol Ltd
Conditions:
Cognitive Function
Mood
Eligibility:
All Genders
50-70 years
Phase:
NA
Brief Summary
Dietary intake of omega-3 polyunsaturated fatty acids (n-3 PUFAs) is inversely associated with cognitive decline and dementia (e.g. Kalmijn et al. 2004, Heude et al. 2003, Morris et al. 2005, Dullemei...
Eligibility Criteria
Inclusion
- Generally healthy
- Aged 50-70 years
- Low consumer of oily fish (≤ 1 portion/month)
- Has not taken vitamin/herbal supplements in the past 3 months
- Has not taken omega-3 supplement (including cod liver oil) in the past 2 years
- Has a good level of written and spoken English
- Has an MMSE score \> 24
- Is suffering from a memory complaint (MAC-Q score \> 24)
Exclusion
- BMI \> 35
- Smokes more than 15 cigarettes per day
- History of alcohol/drug abuse
- Currently taking statins/antidepressant/blood thinning medication
- Has high blood pressure
- Suffers from migraines/anaemia/heart or lung disorder/diabetes/active infections/jaundice/haemophilia or other clotting disease
- Has learning difficulties/dyslexia/colour blindness
- Is HIV positive
- Has hepatitis
Key Trial Info
Start Date :
July 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2012
Estimated Enrollment :
261 Patients enrolled
Trial Details
Trial ID
NCT01185379
Start Date
July 1 2010
End Date
June 1 2012
Last Update
September 26 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Northumbria University
Newcastle upon Tyne, Tyne and Wear, United Kingdom, NE1 8ST